1. Introduction {#s0005}
===============

Aspirin is commonly used to prevent cardiovascular disease and colon cancer -- leading causes of death and disease worldwide. There are large knowledge gaps in how this drug produces such diverse effects. Aspirin inhibits platelet function through platelet COX-1 suppression ([@bb0035]). However, this "on-target" mechanism is insufficient to explain aspirin\'s full effects on platelets since aspirin resistance (defined as aspirin\'s ability to inhibit platelet COX-1) is rare ([@bb0110]) and uninhibited COX-1 does not explain variation in aspirin\'s effects on platelet function ([@bb0270]). Further, this mechanism is not implicated in cancer ([@bb0115]). In our prior work ([@bb0265]) we used aspirin as a probe in an experimental human system and assayed aspirin\'s pharmacodynamic effects using several assays of platelet function to comprehensively identify the effects of aspirin on platelet function. In 50 healthy volunteers administered 325 mg/day aspirin and simultaneous peripheral blood gene expression profiling before and after aspirin exposure, we identified an aspirin response signature (ARS) as a set of 62 tightly co-expressed genes in peripheral blood RNA that was correlative of the effects of aspirin on ADP, epinephrine, and collagen induced platelet aggregation ([@bb0265]). We subsequently validated the ARS in an independent cohort of 53 healthy volunteers and 132 patients with cardiovascular disease ([@bb0265]). That we did not observe a correlation between the ARS and platelet function in the absence of aspirin exposure suggested that part of the biologic effect of aspirin may be to modify platelet function via changes in gene expression. Here, we show that *RUNX1*, a key regulator of numerous genes governing both platelet and megakaryocyte biology, is an aspirin-responsive transcription factor and this represents an effect of aspirin on platelet/megakaryocyte biology and protection against cardiovascular events. *RUNX1* is also a tumor suppressor gene in the colon ([@bb0085]) and we show that *RUNX1* and aspirin-responsive genes regulated by RUNX1 are dysregulated in colon cancer and are associated with cancer-free survival.

2. Materials and Methods {#s0010}
========================

2.1. Megakaryocytes {#s0015}
-------------------

Human erythroleukemia (HEL) cells (ATCC, Manassas,VA) were grown in RPMI-1640 medium (Mediatech,Flemington, NJ) supplemented with 10% fetal bovine serum (HyClone, ThermoFisher Scientific, Pittsburgh, PA) and 1% of antibiotics (penicillin and streptomycin from ATCC, Manassas, VA). To induce megakaryocytic transformation, HEL cells were grown in the presence of phorbol 12-myristate 13-acetate (10 nM PMA) for 24 h ([@bb0140]). Megakaryocytic HEL cells (1 × 10\^6) were treated with acetylsalicylic acid (ASA, Sigma, St. Louis, MO) or sodium salicylic acid (SS, Thermo Fisher Scientific, Pittsburgh, PA) (0.1, 0.5 and 1 mM) for 24, 48 and 72 h. In control experiments cells were treated with DMSO (Dimethylsulfoxide). In 48 and 72 h experiments, medium was replenished with fresh ASA or SS every 24 h. Cells were harvested and centrifuged (at 2000 rpm for 2 min on a table top centrifuge) and the pellets were resuspended in RNAprotect Cell Reagent (Qiagen, Venlo, Limburg) in 1:5 volume.

2.2. Description of Human Cohorts {#s0020}
---------------------------------

Healthy volunteers (n = 53) were exposed to 325 mg/day aspirin for four weeks according to a previously published experimental protocol ([@bb0270], [@bb0265]). Peripheral blood for RNA analysis and purified platelets for proteomic analyses were banked before and after aspirin exposure as previously described ([@bb0265]).

Two cohorts of patients with cardiovascular disease, baseline clinical, medication, and peripheral blood microarray data, and long-term clinical outcomes from the Duke Catheterization Genetics (CATHGEN) cohort have been previously described ([@bb0265]).

All human subject participants provided signed informed consent and protocols were approved by the Duke University Institutional Review Board according to standards indicated by the Declaration of Helsinki.

2.3. RNA Purification {#s0025}
---------------------

RNA was isolated from HEL cells from cultured megakaryocytes using the QIAgen miRNAeasy Mini Kit (cat.no. 217004) following the manufacturer\'s QIAcube protocol and from peripheral blood as previously described ([@bb0265]).

2.4. qPCR {#s0030}
---------

After determining sufficient RNA quality and quantity, cDNA was synthesized using SuperScript VILO Master Mix (Life Technologies; Grand Island, NY) in 20ul reactions using 500 ng of RNA. The reactions were run according to the manufacturer\'s recommended protocol. Aliquots of RNA samples were diluted to matching concentrations prior to cDNA synthesis. This reaction generated cDNA at a final estimated concentration of 25 ng/μl. PCR was performed in 10ul triplicate wells with 2.5 ng cDNA/well with the following kit: BioLine Lo-Rox SYBR \#BIO-94020 and the following protocol: 95° 2 min, 95° 5 s, 55° 20 s, 95° 15 s, 55° 1 min. Gene expression for targets of interest were normalized to the geometric mean expression of normalizing genes (FPGS and GAPDH) as previously described ([@bb0265]). Primers used in this study are available upon request.

2.5. Statistical Analysis {#s0035}
-------------------------

### 2.5.1. Enrichment Analyses {#s1115}

ChIP -- seq peaks for RUNX1 were obtained from the supplemental data of [@bb0260]. The coordinates of the peaks were converted from hg18 to hg19 using liftOver (<https://genome.ucsc.edu/cgi-bin/hgLiftOver>) and gene annotation was determined using Homer (<http://homer.salk.edu/homer/ngs/index.html>). Peaks that were annotated as intergenic were assigned to genes with transcription start sites (TSS) within 100 kb of the peak. HUGO gene symbols where then used to match ChIP-seq peaks with Affymetrix gene expression probe identifiers. A one-sided Fisher\'s exact test was used to test enrichment of RUNX1 binding sites (ChIP-seq peaks) and predicted combinations of transcription factors among genes in the Aspirin Response Signature compared to all other expressed genes. The enrichment p-value was verified though permutations testing random gene sets.

### 2.5.2. PCR Analysis {#s0040}

Normalized expression data as previously described ([@bb0265]). The fold change relative to vehicle control was calculated by dividing the expression for each time point by the average expression of the vehicle control from that experiment and that time point. Unpaired t-tests were used to compare fold changes in expression at each time point vs. vehicle control.

### 2.5.3. Platelet Proteomic Analyses {#s0045}

Platelet proteomic data was normalized as previously described ([@bb0265]) and filtered to focus on those protein products of genes that we identified as down-regulated in a platelets of a patient with RUNX1 haploinsufficiency ([@bb0250]).

Healthy Volunteer expression analysis -- platelet function score and microarray gene expression data from health volunteers (available through the Database of Genotypes and Phenotypes \[dbGaP\] phs000551.v1.p1) before and after exposure and the aspirin response signature (ARS) was calculated as previously described ([@bb0265]). Correlations between individual probe sets, aspirin response signature (ARS), and platelet function score were performed using Spearman correlation.

### 2.5.4. CATHGEN RUNX1 Expression Analysis {#s0050}

Microarray gene expression data was normalized using RMA separately for the two cohorts making up the CATHGEN study: observational (N = 190) and case-control (N = 397) ([@bb0265]) available through dbGaP (phs000551.v1.p1). In each cohort, logistic regression was used to evaluate the effect of each RUNX1 probe expression on myocardial infarction (MI) or death events. Two covariate models were evaluated: 1) the reduced covariate model controlling for the effects of age on time to event, and 2) the full covariate model controlling for the effects of age, sex, race, smoking status, hyperlipidemia, hypertension, diabetes, platelet function, aspirin treatment, and the projected aspirin response gene expression signature. RUNX1 probes were tested for a probe-set effect on MI or death events using the score-based Global Test ([@bb0105]). Two nested logistic regression models were contrasted, the alternative model including all RUNX1 probes and covariates listed above and the null model including only the covariates listed above. Meta-analysis was used to combine evidence of RUNX1 expression on survival in each cohort for both the probe-level and probe-set analyses. For the probe-level analyses, the log odds ratios and their standard errors were pooled as the weighted average of the log odds ratios using inverse variance weights, assuming a fixed effect model. For the probe-set analysis, Fisher\'s method was used to combine p-values from the cohort level Global Test results. All data processing and statistical analyses were conducted in R version 3.2 (<http://www.r-project.org>/) using packages affy, globaltest, and meta for normalization, probe-set tests, and meta-analyses respectively.

### 2.5.5. Colon Cancer Gene Expression Analysis {#s0055}

Microarray gene expression datasets (GEO accessions [GSE14333](ncbi-geo:GSE14333){#ir0020} \[N = 290\] ([@bb0145]) and GSE17536 \[N = 177\] ([@bb0220])) were downloaded and each experiment normalized using RMA. Probe-level analyses were conducted in each experiment using the Cox proportional hazards model, modeling disease free survival time as a function of probe expression while controlling for cancer stage. The ARS probe-set was tested for an effect on disease-free survival using the score-based approach Global Test ([@bb0105]). Results from each experiment were combined using meta-analysis. The probe-level results were pooled assuming a fixed effects model using the weighted average of the log hazards ratios with inverse variance weights. For the probe-set analysis, Fisher\'s method was used to combine the Global Test p-values from each experiment. All data processing and statistical analyses were conducted in R version 3.2 (<http://www.r-project.org>/) using packages affy, survival, globaltest, and meta for normalization, survival analyses, probe-set tests, and meta-analyses respectively.

Differential expression analysis was conducted in [GSE14333](ncbi-geo:GSE14333){#ir0030} and GSE17536 using a moderated *t*-test ([@bb0225]) to contrast probe expression between cancer stages 1 and 2, stages 1 and 3, and stages 1 and 4. Meta-analysis was conducted using the weighted average of the log2 fold change with inverse variance weights. All statistical analyses were conducted in R version 3.2 (<http://www.r-project.org>/) using packages limma differential expression analysis and meta for meta-analyses.

3. Results {#s0060}
==========

3.1. RUNX1 Regulates Aspirin Response Signature Genes {#s0065}
-----------------------------------------------------

To identify potential transcription factor (s) that may be directly regulated by aspirin and as a consequence affect aspirin response signature (ARS) gene expression, we used chromatin immunopreciptation sequencing (ChIP-seq) data ([@bb0260]) generated by using *RUNX1*, *GATA 1* or *2*, *FLI1*, and *SCL* as probes in megakaryocytic cell lines to identify genes with putative binding sites for these transcription factors. Each transcription factor had binding sites that were significantly (p-value ≤ 0.001) enriched in ARS gene promoters demonstrating that each of these transcription factors -- either alone or in combination - in megakaryocytes may transcriptionally regulate ARS genes. Loss of function mutations in *RUNX1* in humans (an autosomal dominant disorder named Familial Platelet Disorder with associated Myeloid Malignancy ([@bb0230])) lead to defects in platelet function including agonist-induced aggregation, secretion, protein phosphorylation, and activation of GPIIb and GPIIIa, thrombocytopenia, and down regulation in several platelet genes including *ALOX12*, *MYL9*, and *PF4* ([@bb0255], [@bb0235], [@bb0240]), thus providing a useful model to study human *RUNX1* loss of function. In a human subject with a truncating mutation in the *RUNX1* DNA binding RUNT domain leading to haplodeficiency, we identified over 200 platelet genes that are down-regulated ([@bb0250]). A majority (60%, 37/62) of ARS genes identified in our prior study ([@bb0265]) are down regulated in *RUNX1* haplodeficiency and 48% (28/62) of ARS genes contain putative RUNX1 binding sites based on ChIP-seq data, with several ([@bb0140], [@bb0150], [@bb0010]) shown to be direct transcriptional targets of RUNX1. Therefore a large proportion of ARS genes appear to be regulated, in part, by RUNX1.

3.2. Aspirin Affects RUNX1 Expression in Megakaryocytic Cells {#s0070}
-------------------------------------------------------------

To test the hypothesis that aspirin directly regulates *RUNX1* (and as a consequence, ARS gene expression), we exposed megakaryocytic cells to aspirin. *RUNX1* expression is known to initiate at two, alternate ([@bb0160]) promoter start sites (P1, distal, and P2, proximal, Supplementary Data) that produces isoforms that have nonredundant ([@bb0020]) roles in hematopoiesis and whose ratio is important for megakaryocyte vs. erythrocyte differentiation ([@bb0070]). We exposed megakaryocytic cell lines to aspirin for up to 72 h and found that aspirin concentrations ≥ 0.5 mM down-regulated *RUNX1* P2 expression ([Fig. 1](#f0005){ref-type="fig"}A) and up regulated *RUNX1* P1 expression ([Fig. 1](#f0005){ref-type="fig"}A) with a suppression of the P2/P1 ratio ([Fig. 1](#f0005){ref-type="fig"}A). When we tested the effects of aspirin\'s main metabolite, salicylic acid - a weak COX-1 inhibitor - we found similar changes in *RUNX1* expression as with aspirin ([Fig. 1](#f0005){ref-type="fig"}B). Thus both aspirin and its primary metabolite have similar effects on RUNX1 expression. To test the hypothesis that aspirin-induced changes in *RUNX1* expression alters RUNX1 function and regulation of downstream genes, we examined *ALOX12* and *MYL9 -* two genes that we have shown are direct transcriptional targets of RUNX1 ([@bb0150], [@bb0140]) and are members of the ARS gene set ([@bb0265]). We found that aspirin down-regulated *MYL9*, which encodes myosin light chain, a component of the motor protein myosin. *ALOX12* expression was not decreased ([Fig. 1](#f0005){ref-type="fig"}C), suggesting that not all RUNX1 targets genes are affected. Overall, a pharmacodynamic effect of aspirin and its metabolite salicylate are to down regulate P2 and upregulate P1 *RUNX1* expression in megakaryocytic cells and as a consequence, RUNX1 function, thus altering the expression of a downstream gene known to influence platelet function.

3.3. RUNX1 Regulated Genes Are Aspirin Responsive {#s0075}
-------------------------------------------------

To test the effects of aspirin on the *RUNX1* pathway *in vivo*, we administered 325 mg/day non-enteric coated aspirin for four weeks to healthy volunteers in an experimental setting where compliance was ensured ([@bb0270]). Because, very low RUNX1 expression in purified platelets (Ct values \> 30 in over half of samples) precluded accurate quantification for comparative purposes of gene expression analysis by PCR, we assayed for RUNX1 expression in peripheral blood. To study *RUNX1* regulated genes and proteins we analyzed purified platelets before and after aspirin exposure. Similar to the response observed in HEL cells, in peripheral blood from healthy volunteers, aspirin exposure resulted in an up-regulation in *RUNX1* P1 and down-regulation in the P2/P1 ratio ([Fig. 2](#f0010){ref-type="fig"}A). Therefore, *RUNX1* gene expression in peripheral blood may represent a pharmacodynamic biomarker for the gene expression modulating effects of aspirin. In purified platelets from the same subjects, aspirin exposure was associated with higher *MYL9* gene expression in platelets ([Fig. 2](#f0010){ref-type="fig"}B), indicating that aspirin alters the expression of this gene. *ALOX12* levels were not altered ([Fig. 2](#f0010){ref-type="fig"}B). We performed open label proteomics on platelet protein ([@bb0265]) and filtered this dataset of 235 proteins to those 22 genes that are differentially expressed in the patient with *RUNX1* haplodeficiency ([@bb0250]). Nearly all proteins (21/22) were responsive to aspirin exposure, including MYL9 ([Fig. 2](#f0010){ref-type="fig"}C); the majority (19/21) were up-regulated.

3.4. RUNX1 Regulated Platelet Proteins Are Associated With Platelet Function {#s0080}
----------------------------------------------------------------------------

To test the hypothesis that aspirin-responsive, *RUNX1-*regulated proteins underlie variation in platelet function, we correlated platelet protein expression with a composite metric (named the platelet function score ([@bb0270])) of ADP, epinephrine, and collagen induced platelet aggregation before and after aspirin exposure. All 21 aspirin-responsive proteins, including MYL9, were correlative of platelet function ([Fig. 2](#f0010){ref-type="fig"}D and [Table 2](#t0010){ref-type="table"}) regardless of aspirin exposure. Aspirin exposure did not change the platelet count (data not shown). The consistency of effects across *RUNX1-*regulated proteins demonstrates that aspirin affects the *RUNX1* pathway *in vivo* and provide an additional mechanism for aspirin\'s effects on modulating platelet function.

3.5. RUNX1 Expression Is Associated With Cardiovascular Events {#s0085}
--------------------------------------------------------------

Aspirin prevents cardiovascular death and myocardial infarction (MI). Based on our findings above in megakaryocytes and humans, we hypothesized that this aspirin-responsive pathway is associated with death or MI. To test this hypothesis we utilized data from two independent cohorts (case-control and observational) of patients with cardiovascular disease who were treated with aspirin for which we have previously demonstrated an association between ARS gene expression in peripheral blood with death or MI·([@bb0265]) To explore the relation between aspirin, platelet function, and cardiovascular events with *RUNX1* gene expression we used *RUNX1* probe sets that were available on the U133 microarray and that map to the *RUNX1* locus on chromosome 21 (Supplementary Data). To ensure that these probe sets could represent *RUNX1* expression and distinguish between *RUNX1* P1 vs. P2 expression we applied two criteria: 1) inclusion of those probe sets that uniquely map to a single gene (i.e. exclusion of probe sets with 's_at' or 'x_at' suffixes) and 2) correlation with PCR-based *RUNX1* P1 or P2 expression in healthy volunteers, respectively. Based on these criteria four probe sets (Supplementary Data) met our criteria and were used to represent *RUNX1* P1 (233690_at and 220918_at) and P2 (1557527_at and 210365_at) expression.

To test the hypothesis that *RUNX1* probe set expression was correlated with either ARS gene expression or platelet function we used healthy volunteer data before and after aspirin exposure ([@bb0265]). The *RUNX1* P2 probe set 210365_at was associated with ARS expression at baseline and after aspirin exposure; neither P2 probe set was associated with platelet function ([Table 1](#t0005){ref-type="table"}). In contrast, P1 probe set 220918_at was associated with ARS gene expression and platelet function after aspirin exposure. Therefore, peripheral blood *RUNX1* microarray data are consistent with the hypothesis that the P1 *RUNX1* isoform regulates ARS gene expression and platelet function in an aspirin dependent manner. To test the hypothesis that RUNX1 expression was associated with cardiovascular events we again focused on these four probe sets ([Fig. 3](#f0015){ref-type="fig"}A). The *RUNX1* P2 probe sets were not associated with death or MI, however, both P1 probe sets were consistently protective for death or MI ([Fig. 3](#f0015){ref-type="fig"}A). This finding extends the pharmacologic effect of aspirin on upregulating *RUNX1* P1 expression to the antiplatelet effects of aspirin on platelet function and cardiovascular events.

3.6. Aspirin Response Signature Genes Are Associated With Colorectal Cancer Stage and Survival {#s0090}
----------------------------------------------------------------------------------------------

Beyond its use in cardiovascular disease, aspirin use is recommended to prevent GI malignancies ([@bb0030]) and is being tested ([NCT02467582](ctgov:NCT02467582){#ir0040}, [NCT02301286](ctgov:NCT02301286){#ir0045}, and [NCT00565708](ctgov:NCT00565708){#ir0050}) as adjuvant therapy in patients treated for colon cancer. *RUNX1* is a known tumor suppressor gene in acute myeloid leukemia (AML ([@bb0135])) and gastrointestinal (GI) malignancies ([@bb0085], [@bb0075]). *RUNX1* ([@bb0210]) and several ARS genes (*MYL9* ([@bb0280]), *CTTN* ([@bb0095]), *CALD1* ([@bb0095]), *SPARC* ([@bb0050])) are dysregulated in GI malignancies. To test the hypothesis that *RUNX1* and its downstream ARS genes represent a mechanistic link for the chemoprotective effects of aspirin on GI cancers, we tested the association of the microarray expression of *RUNX1* and ARS genes with colorectal cancer stage and cancer free survival in two independent cohorts ([@bb0220], [@bb0145]) not previously studied for these genes. We found that *RUNX1* and the majority of ARS probe sets are expressed in normal colon tissue (53/72) as well as in colon cancer samples (68/72). To test the hypothesis that aspirin responsive *RUNX1* was associated with disease-free survival, we tested the P2 and P1 *RUNX1* probe sets and found that higher expression of *RUNX1* P1 probe sets were associated with survival (meta-analysis hazard ratio for P1 probe sets 233690_at and 220918_at, 95% confidence intervals, and meta-analysis p-values were 1.6 \[1.1 -- 2.3\], 0.01 and 1.6 \[0.9 -- 2.7\], 0.09, respectively). The remaining *RUNX1* probe sets were not associated with survival or with cancer stage (data not shown). Further, the *RUNX1* responsive, ARS gene set was differentially expressed in advanced colon cancer stage (B-D) compared to stage A cancers (genesettest p-values = 1.34e − 06 and 0.001). In particular, several ARS genes including *MYL9*, were up-regulated in stages B--D compared to stage A ([Fig. 3](#f0015){ref-type="fig"}B, Supplementary Data). Furthermore, independent of cancer stage, several ARS genes including *SPARC*, *CTTN*, *CALD1*, and *MYL9* in colorectal cancer tumors were associated with cancer-free survival (meta-analysis odds ratios = 1.3--2.7, meta-analysis p-values \< 0.01, Supplementary Data). To account for potential confounding by clinical characteristics and treatments, we included age, sex, adjuvant chemotherapy, and adjuvant radiation therapy as covariates in the Jorissen et al. analysis. Aspirin use was not available in either. To test for potential confounding effects, we compared effect sizes for each ARS and *RUNX1* probeset in the survival analysis with and without inclusion of these covariates and found a strong correlation of effect sizes (r = 0.94, slope = 1.02, Supplementary Data). These data suggest that the aspirin responsive *RUNX1* -- ARS pathway that we identified in blood may be active in colon cancers and illuminates a potential additional mechanism for aspirin\'s chemoprotective role following colon cancer diagnosis.

4. Discussion {#s0095}
=============

Aspirin is widely used to prevent cardiovascular disease and is recommended ([@bb0030]) to prevent colon cancer. To study the effects of aspirin, we used a systems pharmacogenomics approach that combines systems biology, genetics, and pharmacology. Previously, we used serial gene expression profiling in humans exposed to aspirin ([@bb0265]). We identified an aspirin response signature (ARS) as a set of peripheral blood genes, that correlated with the effects of aspirin on platelet function, suggesting that part of the biologic effect of aspirin on platelet function may be to modify platelet gene expression ([@bb0265]). Because of the co-expressed nature of the ARS and their platelet origin we tested the hypothesis that aspirin produces its effects on gene expression through modulation of a megakaryocytic transcription factor (s). Our findings demonstrate that 1) ARS genes are RUNX1 responsive 2) aspirin and salicylate directly regulate *RUNX1* in a promoter specific (P1 versus P2) fashion; 3) aspirin influences ARS gene expression in megakaryocytes and platelets; 4) *RUNX1* P1 gene expression is associated with improved long-term clinical outcomes in patients with cardiovascular disease and colon cancer. Together, these findings provide evidence for an effect for aspirin on *RUNX1* gene expression and function. This aspirin-responsive mechanism is implicated in cardiovascular disease and colon cancer outcomes.

It is well known that aspirin\'s mechanism of action is to inhibit platelet COX-1. However, aspirin likely has additional mechanisms for inhibiting platelet function because aspirin doses in excess of 81 mg/day do not result in additional COX-1 suppression but produce additional platelet inhibition as assessed by ADP and collagen ([@bb0120]). Although aspirin and salicylate, are well-known to inhibit NFKB ([@bb0155], [@bb0090]), IkB phosphorylation ([@bb0180]), and other cellular kinases ([@bb0245], [@bb0215]), many of these effects are observed at concentrations not achieved ([@bb0190]) with cardioprotective dosages (≤ 325 mg/day). In support of our hypothesis that aspirin alters gene expression, Massimi et al. identified that aspirin can upregulate expression of a single gene, *MRP4*, in megakaryocytes and platelets -- an effect that was attributed to variation in platelet function in response to aspirin ([@bb0165]). In this study we link the effects of aspirin and salicylate to *RUNX1*, a well-known transcription factor critical for normal hematopoiesis, megakaryocyte differentiation, and platelet function and a number of genes that it regulates ([@bb0080]). That we observed similar effects with salicylate compared to aspirin on megakaryocyte gene expression suggests that aspirin\'s ability to inhibit COX-1 may not be required for this effect because salicylate has a \~ 20-fold lower potency for inhibiting COX-1 ([@bb0185]). Therefore in addition to the well-known effects of aspirin on platelet COX-1, our findings identify an effect of aspirin (or its metabolite salicylate) on *RUNX1* and downstream gene expression.

*RUNX1* is critical for normal hematopoiesis and megakaryocyte differentiation. Deletion of *RUNX1* leads to embryonic lethality in mice due to hemorrhage ([@bb0275]), and humans with mutations leading to *RUNX1* haploinsufficiency ([@bb0230]) are characterized by thrombocytopenia, defects in multiple aspects of platelet function, and a predisposition to leukemia ([@bb0255], [@bb0235], [@bb0130]). These prior studies in humans demonstrate that reductions in RUNX1 expression can lead to profound changes in platelet function. Our data demonstrate that aspirin can produce \~ 2 fold changes in *RUNX1* in the megakaryocyte and in *MYL9 -* a gene that we have shown is directly regulated by RUNX1 ([@bb0140]). *MYL9* plays a major role in platelet function and formation ([@bb0100]) and in megakaryocyte biology ([@bb0140]). Therefore the observed effects of aspirin on *RUNX1* and downstream gene expression provides an additional mechanism by which aspirin modulates platelet function and prevents cardiovascular disease.

Colorectal cancer is among the most common malignancy in the US and developed countries. Despite several lines of evidence implicating COX-2 ([@bb0005], [@bb0205], [@bb0195], [@bb0055], [@bb0200], [@bb0025], [@bb0015]) as the mechanism by which aspirin prevents colon cancer, low-dose (\< 100 mg/day) aspirin, which is associated with a reduced risk of colon cancer ([@bb0060], [@bb0040]), is a weak COX-2 inhibitor ([@bb0170]). Therefore additional mechanisms linking aspirin to colon cancer prevention are likely. Our findings demonstrate that *RUNX1* and several ARS genes, which are RUNX1-responsive, are correlated with disease free survival in two independent datasets of colon cancer patients. Therefore, ARS genes, which we have shown are aspirin- and RUNX1-responsive in the hematopoietic system, are also associated with colon cancer outcomes.

There are some limitations to our findings that deserve consideration. First, in megakaryocytic cells, we observed a down regulation in *MYL9* compared to an upregulation in human platelets. The different directions of change in *MYL9* expression may be attributed to 1) differences in duration of aspirin exposure (72 h \[in vitro\] vs. 4 weeks \[in vivo\]); the longer duration may permit compensatory mechanisms to develop; 2) the impact of cell specific transcriptional regulators (HEL-derived early stage megakaryocytic cells vs. native megakaryocytes), or 3) *MYL9* measured in megakaryocytic cells vs. platelets. Second, while aspirin changed *MYL9* expression there was no change in *ALOX12*. One explanation is that blocking COX-1 with aspirin may shunt arachidonic acid into the lipoxygenase pathways and thus cause a compensatory increase in *ALOX12* that balances any effects of aspirin on RUNX1. Third, the dose- and time-dependent effects of aspirin or salicylate were not linear ([Fig. 1](#f0005){ref-type="fig"}). These non-linearities will likely be understood as part of future research around the mechanism of aspirin on *RUNX1* expression. Fourth, the salicylate concentrations in this study may be higher than those achieved clinically. Because aspirin is quickly metabolized to salicylate, there is no systemic accumulation of aspirin. However, there is significant accumulation of salicylate (which has a half-life of 3--4 h) in the 30--100 μM range ([@bb0175], [@bb0045]) for 75--100 mg aspirin and 400--800 μM ([@bb0065], [@bb0175]) with 300 mg aspirin dosing based on area under the concentration-time curve analyses. These data, combined with the finding that we see similar effects of aspirin on *RUNX1* with 325 mg/day dosing suggests that the concentrations used are physiologic. Last, we used an aspirin dose that is at the upper limit of the dosage range for cardiovascular prevention (75--325 mg/day). We chose this dose because 325 mg/day remains dosage commonly used in clinical practice ([@bb0125]) and one that is currently being tested in randomized clinical trials in cardiovascular disease ([theaspirinstudy.org](http://theaspirinstudy.org){#ir0055} - NCT02697916) and colon cancer ([www.capp3.org](http://www.capp3.org){#ir0060} - NCT02497820). We recognize the importance of understanding the dose-response relationship between aspirin and RUNX1. Future studies will examine the extent to which changes in gene expression seen in this study extend to lower aspirin doses. Despite these limitations, we show that *RUNX1* is an aspirin responsive transcription factor, leading to alteration in numerous downstream platelet genes and proteins that regulate platelet function and whose levels are correlated with known platelet physiology.

Our work on aspirin represents a proof-of-concept application of the systems pharmacogenomics approach to identify novel effects for aspirin that were not predicted based on aspirin\'s known mechanism of COX-1 inhibition. Future work focused on identifying the mechanism underlying this effect may lead to novel molecules that exploit this property for cardiovascular disease and cancer prevention. *RUNX1* pathway biomarkers may be useful to individualize and optimize antiplatelet therapy or identify novel conditions that may be treated by aspirin. By using a systems pharmacogenomics approach we identify an off-target mechanism of action for one of the most commonly used medications worldwide and implicate this mechanism to cardiovascular disease and colorectal cancer.
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![Aspirin and salicylate effects on *RUNX1* P2 and P1. Megakaryocytic HEL cells were exposed to escalating concentrations and durations of aspirin (panel a) or salicylic acid (panel b). Changes in *RUNX1* P1, P2, and the P2/P1 ratio in response to aspirin or salicylic acid are displayed relative to DMSO. Effects of aspirin on two *RUNX1* regulated genes, *MYL9* and *ALOX12* (panel c). Data are mean ± standard error of the mean. (\*) = p-values \< 0.05 and (−) = p-values for ≤ 0.08 for unpaired parametric two-tailed t-tests of fold change of aspirin or salicylate compared to DMSO for each time point. Each bar represents the average of 4--5 experiments.](gr1){#f0005}

![Effects of aspirin exposure on RUNX1 function in humans. a, In peripheral blood RNA, *RUNX1* P1, P2, and the P2/P1 ratio is displayed at baseline and after 4 weeks of 325 mg/day aspirin exposure in healthy volunteers (n = 45). Data are mean ± standard error of the mean (SEM, y-axis, scaled 0.75--1.25). Panels b and c, in purified platelet RNA (B) and platelet protein (C) from healthy volunteers exposed to 325 mg/day aspirin, *MYL9* expression before and after aspirin exposure is displayed. Data are SEM (y-axis, scaled 0.75--1.25). \* = p-values \< 0.05 for unpaired parametric two-tailed t-tests compared to DMSO at for each time point. Panel d, Using a previously described ([@bb0265]) composite metric of nine platelet function measures termed the Platelet Function Score, MYL9 protein expression (x-axis) is plotted versus the platelet function score (y-axis) before and after aspirin exposure in healthy volunteers. P-value represents ANOVA p-value comparing mixed-effects models with vs. without MYL9 protein expression. Shaded area represents 95% confidence interval around regression line.](gr2){#f0010}

![*RUNX1 and MYL9* association with cardiovascular events or colon cancer stage Panel a, Using whole blood RNA microarray data collected from patients at the time of cardiac catheterization and long-term follow up for death and myocardial infarction (MI), we assembled case-control (n = 190) and observational patient cohorts (n = 397) where we have previously shown ([@bb0265]) an association between an Aspirin Response Signature (ARS) and death/MI events. The associations of P2 and P1 *RUNX1* probe sets (see text for definitions) with death or MI in the observational and case-control individually and combined through meta-analysis are displayed as log Odds Ratios and 95% confidence intervals. Log odds ratios less than zero correspond to protective effects (i.e. higher expression associated with lower risk) and vice versa. All analyses are adjusted for age and sex. Panel b, Normalized expression for *RUNX1* P1 probe sets are plotted vs. death or MI outcomes in the combined observational and case-control cohorts. Panel c, using two publically available datasets of colorectal cancer tumors ([@bb0145], n = 290 and [@bb0220], n = 177), a meta-analysis of differential *MYL9* expression for stages B--D vs. A was conducted and the log2 fold change and 95% confidence intervals for each pairwise comparison is presented.](gr3){#f0015}

###### 

Correlation of *RUNX1* probe sets with Aspirin Response Signature expression and platelet function before and after aspirin exposure in healthy volunteers.

Table 1

  Probe set ID            Correlation coefficients                                                                                                              
  ----------------------- --------------------------------------- ------------------------------------------ ----------------------------------------- -------- ----------------------------------------
  P2 *RUNX1* probe sets                                                                                                                                         
  210365_at               0.31[⁎](#tf0005){ref-type="table-fn"}   0.39[⁎⁎](#tf0010){ref-type="table-fn"}     0.30[⁎⁎](#tf0010){ref-type="table-fn"}    − 0.01   − 0.07
  1557527_at              − 0.12                                  − 0.12                                     − 0.01                                    0.16     0.15
                                                                                                                                                                
  P1 *RUNX1* probe sets                                                                                                                                         
  233690_at               − 0.11                                  − 0.05                                     0.13                                      − 0.15   0.10
  220918_at               − 0.18                                  − 0.45[⁎⁎](#tf0010){ref-type="table-fn"}   − 0.27[⁎](#tf0005){ref-type="table-fn"}   − 0.03   0.34[⁎⁎](#tf0010){ref-type="table-fn"}

p ≤ 0.05.

p ≤ 0.01.

The platelet function score (11) (PFS) was used to quantify platelet function before and after aspirin exposure.

###### 

Correlation with platelet function and change in response to aspirin exposure for *RUNX1* regulated platelet proteins.

Table 2

  Protein symbol   Regression coefficient for correlation with platelet function   Regression p-value   Mean difference (pre-post)   Paired *t* test p-value
  ---------------- --------------------------------------------------------------- -------------------- ---------------------------- -------------------------
  FLNA             0.11                                                            0.01                 3.91                         0.01
  F13A             0.20                                                            0.01                 1.83                         0.02
  PDE5A            − 0.35                                                          0.34                 − 0.06                       0.78
  SH3L2            − 1.31                                                          0.01                 − 0.26                       0.03
  ILEU             − 1.10                                                          0.02                 − 0.28                       0.03
  PGH1             − 1.36                                                          0.00                 − 0.30                       0.03
  VDAC3            − 1.11                                                          0.02                 − 0.33                       0.01
  JAM1             − 0.84                                                          0.03                 − 0.36                       0.02
  1433F            − 1.04                                                          0.01                 − 0.39                       0.02
  NP1L1            − 0.70                                                          0.02                 − 0.46                       0.02
  CALD1            − 0.65                                                          0.01                 − 0.69                       0.02
  PRDX6            − 0.55                                                          0.01                 − 0.70                       0.02
  LEGL             − 0.58                                                          0.01                 − 0.72                       0.01
  TBA4A            − 0.48                                                          0.01                 − 0.80                       0.01
  SDPR             − 0.44                                                          0.01                 − 0.84                       0.01
  LTBP1            − 0.48                                                          0.01                 − 0.85                       0.01
  MYL9             − 0.45                                                          0.01                 − 0.89                       0.01
  TAGL2            − 0.32                                                          0.01                 − 0.99                       0.06
  PLF4             − 0.33                                                          0.03                 − 1.05                       0.01
  TPM4             − 0.28                                                          0.01                 − 1.40                       0.01
  TBB1             − 0.28                                                          0.01                 − 1.58                       0.01
  ACTN1            − 0.20                                                          0.01                 − 2.22                       0.01
